Metformin

DUBLIN--(BUSINESS WIRE)--The "Drug Repurposing - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Drug Repurposing was valued at US$29.4 Billion in 2024 and is projected to reach US$37.3 Billion by 2030, growing at a CAGR of 4.1% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Drug Repurposing market. Drug repurposing - also known as drug repositioning - involves identifying new therapeutic uses for existing or previously shelved drugs. This approach is experiencing a renaissance as pharmaceutical companies, researchers, and health authorities seek faster, more cost-effective pathways to address unmet medical needs. Traditional drug development can take over a decade and cost billions, with high rates of clinical failure. In contrast, repurposed drugs have already cleared significant safety and pharmacokinetic hurdles, enabling developers to bypass early-stage trials and significantly reduce time to market. This has made repurposing a highly attractive strategy, particularly in areas like rare diseases, oncology, neurodegenerative disorders, and infectious diseases. What Is Driving Growth and Strategic Investment in Drug Repurposing? The growth in the drug repurposing market is driven by several factors related to technological enablement, regulatory facilitation, and evolving pharmaceutical strategies. AI and bioinformatics platforms are significantly improving the success rate of repurposing projects by predicting mechanisms of action and identifying off-target effects with high precision. The availability of large-scale biomedical datasets - including omics profiles, disease registries, and patient-level data - provides fertile ground for cross-indication mapping and drug efficacy modeling. These technologies reduce the risk, cost, and time traditionally associated with de novo drug development. End-use adoption is also accelerating. Biotechnology firms are increasingly pursuing repurposing as a core business model, while large pharma companies are integrating repurposing into life-cycle management to extend the value of off-patent or low-performing assets. Regulatory bodies are introducing streamlined pathways for approvals - such as the 505(b)(2) route in the U.S. - which allows developers to leverage existing safety and efficacy data while only requiring supplemental clinical evidence for new indications. This has created a favorable environment for licensing, joint ventures, and venture capital investment in repurposing ventures. Furthermore, patient advocacy groups and rare disease foundations are lobbying for and funding repurposing studies, driving both awareness and clinical momentum. These combined forces are ensuring that drug repurposing remains a strategic and rapidly growing pillar in the global pharmaceutical innovation ecosystem. What Are the Emerging Trends Transforming the Drug Repurposing Landscape? A major trend reshaping the repurposing market is the integration of artificial intelligence (AI) and machine learning (ML) into drug discovery pipelines. Computational models can now analyze massive datasets - ranging from genomic data to real-world evidence and electronic health records - to identify novel drug-disease relationships. AI-driven platforms are enabling in silico screening of compound libraries to prioritize candidates for preclinical and clinical evaluation. This is especially impactful in rare disease treatment and precision oncology, where traditional pipelines often struggle due to limited patient populations and high R&D costs. Collaborative consortia and public-private partnerships are also on the rise. Initiatives like the NIH's NCATS (National Center for Advancing Translational Sciences) and Open Targets are pooling data and resources across academia, industry, and government to accelerate repurposing efforts. Additionally, patent expiration of blockbuster drugs is fueling new interest in repurposing by generics and specialty pharma companies. Regulatory frameworks are evolving too - efforts to provide clearer guidance for 505(b)(2) approvals in the U.S. and adaptive licensing models in Europe are making it easier to navigate the intellectual property and clinical validation landscape. These trends are creating fertile ground for innovation, collaboration, and accelerated drug development across disease areas. Which Therapeutic Areas Are Benefiting Most from Repurposing Strategies? The impact of drug repurposing is most visible in complex and underserved therapeutic areas. In oncology, for instance, repurposed drugs are being explored as adjuvants or second-line treatments. Metformin (a diabetes drug), propranolol (a beta-blocker), and itraconazole (an antifungal) have shown anticancer potential in various studies. In neurodegenerative diseases like Alzheimer's and Parkinson's, drugs targeting inflammation, cholesterol metabolism, and mitochondrial function are being repositioned to slow disease progression - areas where novel therapies have struggled. This repurposing model offers new hope in high-failure domains by leveraging known pharmacodynamics to target secondary pathways. In infectious diseases, especially with rising antimicrobial resistance (AMR), repositioned antivirals and antibiotics are filling critical gaps. For example, certain anticancer agents have shown unexpected antibacterial or antifungal effects, while psychiatric drugs are being investigated for their immunomodulatory roles in viral infections. Autoimmune and inflammatory diseases, including lupus, rheumatoid arthritis, and multiple sclerosis, also stand to benefit, as researchers uncover overlapping pathways with other disease classes. Even mental health treatments are seeing cross-utility - ketamine's use in treatment-resistant depression is a prime example. These cross-therapeutic applications are broadening the value proposition of many legacy drugs, supporting their reintegration into modern treatment paradigms. Report Scope Key Insights: Report Features: Segments Tariff Impact Analysis: Key Insights for 2025 What's Included in This Edition: Buyers receive a free July 2025 update with: Key Attributes: Key Topics Covered: MARKET OVERVIEW MARKET TRENDS & DRIVERS FOCUS ON SELECT PLAYERS: Some of the 41 companies featured in this report For more information about this report visit https://www.researchandmarkets.com/r/49iyr8 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces that new clinical and scientific data on TWYMEEG® will be presented at the 68th Annual Meeting of the Japan Diabetes Society (JDS 2025), taking place from May 29 to 31, 2025, in Okayama, Japan. A total of 15 presentations1, including results from 7 clinical trials, 3 post-hoc analyses2 and 5 non-clinical studies supported by Sumitomo Pharma, will be delivered by leading Japanese diabetes experts. These findings further confirm TWYMEEG®’s efficacy in monotherapy and combination therapies, safety, dual mechanism of action and potential benefits in specific patient populations. Main topics include: TWINKLE ( TW YMEEG ® in d i abetic patients with re n al impairment: A post-mar k eting l ong-t e rm study) study (Phase 4 study) : confirmation of TWYMEEG ® efficacy and safety in diabetic patients with renal impairment FAMILIAR Study : confirmation of TWYMEEG ® efficacy and safety in combination with DPP-4 inhibitors PARADIME Clamp : confirmation of TWYMEEG ® dual mechanism of action in diabetic patients – clinical data showing effects on insulin sensitivity (clamp part) and glucose stimulated insulin secretion (OGTT part) PARADIME TIR : confirmation of TWYMEEG ® effects on glucose variability PET/MRI Study : confirmation of TWYMEEG ® effect on glucose excretion in the gut Thomas Kuhn, Chief Executive Officer of Poxel, stated: “We are proud to see the scientific community’s continued interest and the commitment of our partner Sumitomo Pharma to document and promote TWYMEEG®’s attributes and value. These presentations further support the product’s clinical and commercial trajectory in Japan. They also highlight its value proposition for Japan and other territories and its unique profile across diverse patient subgroups.” About Poxel SA Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare disorders. For the treatment of MASH, PXL065 (deuterium-stabilized R-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG® (Imeglimin), Poxel’s first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan. For more information, please visit: www.poxelpharma.com All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is not otherwise responsible for the content of external hyperlinks referred to in this press release. Appendix Title Main Results Speaker Institution Type A post-marketing clinical trial to evaluate the safety, tolerability, and efficacy of Imeglimin in Japanese type 2 diabetes patients with renal impairment (Twinkle Study results;Phase 4) Imeglimin was shown to be safe and effective in patients with T2D associated with renal dysfunction with eGFR less than 45 mL/min/1.73 m2 Dr. Babazono Ishikawa Memorial Association Clinical Efficacy and safety of Imeglimin as an add-on treatment in type 2 diabetes patients treated with DPP-4 inhibitors: interim analysis of the FAMILIAR study Combination therapy of Imeglimin and DPP-4 inhibitors significantly reduced HbA1c at 24 weeks in type 2 diabetes patients with inadequate glycemic control with DPP-4 inhibitor therapy, confirming that Imeglimin may be a new treatment option when combined with a DPP-4 inhibitor regardless of age. Dr. Kaku Kawasaki Medical School Clinical Comparison of the effects of Imeglimin and metformin on insulin and incretin secretion Imeglimin enhanced insulin secretion as well as increased not only GLP-1 but also GIP secretion, unlike metformin Dr. Omori Kansai Electric Power Hospital Clinical Effect of Imeglimin use on Time in Range in type 2 diabetes: A multicenter randomized controlled trial (Paradime-TIR) Imeglimin alone and in combination with DPPIV inhibitors increased Time in Range by more than 10% without increasing Time Below Range, confirming the efficacy of the product in reducing glycemic variability Dr. Ueda Kobe Univ. Clinical The effects of Imeglimin and metformin on insulin secretion and sensitivity (Paradime-Clamp; OGTT part) No differences were observed between Imeglimin and Metformin on glucose lowering effects, and on insulin secretion and insulin sensitivity effects Dr. Yamada Kobe Univ. Clinical The effects of Imeglimin and metformin on insulin secretion and sensitivity (Paradime-Clamp; Clamp part) No differences were observed between Imeglimin and Metformin on insulin secretion, insulin sensitivity and their ability to switch energy sources Dr. Katsura Kobe Univ. Clinical Effects on glucose excretion to gut by using FDG/PET MRI study Imeglimin improved glucose excretion into the intestinal lumen Dr. Fukumitsu Kobe Univ. Clinical Post-hoc analysis (Atypical cluster analysis of Imeglimin + Metformin) The highest A1c reduction of the combination Imeglimin + metformin was observed in obese patients or those with a high baseline HbA1c Kitayama SMP Clinical Post-hoc analysis: Insulin combination therapy Combination therapy with Imeglimin and insulin exerted glucose lowering effects independent of obesity type Hagi, PhD SMP Clinical Post-hoc analysis: Monotherapy Imeglimin monotherapy exerted glucose lowering effects independent of obesity type Maruyama SMP Clinical Vascular protection effects of Imeglimin, a mitochondrial function-improving drug Imeglimin showed protective effect against vascular lesions like SGLT2 inhibitors and GLP-1 receptor agonists Dr. Iwazawa Juntendo Univ. Shizuoka Hospital Non-clinical Effect of Imeglimin on diabetic neuropathy in type 1 diabetic rat models Imeglimin may be effective against diabetic neuropathy as shown in this study in STZ-induced diabetic rats, Dr. Nihei Aichi Gakuin Univ. Non-clinical Combined effects of anaerobic exercise and Imeglimin on skeletal muscles The combination of Resistance Training and Imeglimin may be an effective treatment by improving mitochondrial function, glucose metabolism and glucose uptake Dr. Ishiguro Niigata Univ. Non-clinical Effect of Imeglimin on periodontitis associated with type 1 diabetes Imeglimin may be useful in preventing the worsening of periodontal disease due to type 1 diabetes. Dr. Kondo Aichi Gakuin Univ. Non-clinical Imeglimin effect on intestinal gene expression Imeglimin induced similar gene expression as metformin in the whole intestinal tissue, but single-cell analysis revealed different effects on specific cell types, including intestinal cell clusters and macrophage clusters Dr. Hozumi Kobe Univ. Non-clinical 1 Detailed program included in Appendix 2 Refers to a statistical analysis specified after a study has been concluded and the data collected